Correspondence to Dr Laura McWhirter, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh EH8 9YL, UK; laura.mcwhirter{at}ed.ac.uk Performance validity tests (PVTs) are widely used ...

Background Increased rates of brain atrophy on serial MRI are frequently used as a surrogate marker of disease progression in Alzheimer’s disease and other dementias. However, the extent to which they ...

Correspondence to Dr Michael Benatar, Department of Neurology, University of Miami Miller School of Medicine, Miami, Florida, USA; MBenatar{at}med.miami.edu Notwithstanding the challenges, it is ...

Identifying biomarkers of Alzheimer’s disease (AD) will accelerate the understanding of its pathophysiology, facilitate screening and risk stratification, and aid in developing new therapies.

2 Oxford Project to Investigate Memory and Ageing (OPTIMA), Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK Correspondence to Dr P Garrard, Stroke and ...

Correspondence to Dr Timothy Rittman, Department of Clinical Neurosciences, University of Cambridge, Herchel Smith Building, Forvie Site, Addenbrooke's Hospital Site, Robinson Way, Cambridge CB2 0SZ, ...

aInstitute of Clinical Neurosciences, bKanematsu Laboratories, Royal Prince Alfred Hospital, NSW, 2006 Australia Professor JD Pollard, Institute of Clinical Neurosciences, University of Sydney, ...

Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA Dr A Alonso, Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, ...

Objective: Parkinson’s disease (PD) is a progressive neurological disorder characterised by a large number of motor and non-motor features that can impact on function to a variable degree. This review ...

1 Department of Neurosciences and Institute of Molecular Medicine, Faculty of Medicine, University of Lisbon, Lisbon, Portugal 2 Department of Clinical Neuroscience, Barts and the London School of ...